Details for Patent: 10,792,270

« Back to Dashboard

Which drugs does patent 10,792,270 protect, and when does it expire?

Patent 10,792,270 protects VASCEPA and is included in one NDA.

This patent has one hundred and thirteen patent family members in forty-one countries.

Summary for Patent: 10,792,270

Title:	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Abstract:	In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
Inventor(s):	Paresh Soni
Assignee:	Amarin Pharmaceuticals Ireland Ltd
Application Number:	US16/525,388
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

United States Patent 10,792,270: Scope, Claims, Expiration, and Vascepa Patent Landscape

U.S. Patent No. 10,792,270 protects a cardiovascular-risk-reduction method using approximately 4 grams per day of ethyl icosapentate, the active ingredient in Vascepa. Its claims are directed to reducing coronary revascularization risk in patients with established cardiovascular disease, particularly patients receiving statins and having elevated triglycerides.

The patent is a method-of-use patent. It does not independently claim ethyl icosapentate as a chemical compound, a manufacturing process, or every formulation containing the active ingredient. Its commercial relevance depends on whether a competing product is marketed for the claimed cardiovascular-risk-reduction use and whether the competitor’s label, formulation, and dosing regimen fall within the claim limitations.

What patent protects coronary revascularization risk reduction with icosapent ethyl?

U.S. Patent 10,792,270, commonly referred to as the '270 patent, claims administration of about 4 grams per day of ethyl icosapentate to a subject with established cardiovascular disease for a period effective to reduce the risk of coronary revascularization.

Item	Details
Patent	U.S. 10,792,270
Patent type	Method of treatment and cardiovascular-risk-reduction
Active ingredient	Ethyl icosapentate, also known as icosapent ethyl
Commercial product	Vascepa
Core indication	Reduction of coronary revascularization risk
Core dose	About 4 grams per day
Dosage form reflected in dependent claims	Four capsules containing approximately 1 gram each
Key patient population	Subjects with established cardiovascular disease
Additional restrictions	Statin therapy, triglyceride range, LDL-C range, product omega-3 purity, and at least two years of treatment
Patent expiration	Orange Book-listed expiration is generally reported as December 1, 2033
Patent owner and commercial sponsor	Amarin-related entities

The patent is part of the broader Vascepa patent estate developed around the REDUCE-IT cardiovascular outcomes data and the FDA-approved cardiovascular-risk-reduction indication.

How broad is independent claim 1 of U.S. Patent 10,792,270?

Claim 1 has five principal limitations:

1. A subject is treated.
2. The subject has established cardiovascular disease.
3. Ethyl icosapentate is administered.
4. The dose is about 4 grams per day.
5. Treatment continues for a period effective to reduce coronary revascularization risk.

The claim is narrower than a general claim to using icosapent ethyl for cardiovascular benefit. It requires both a specific patient condition and a specific dosage range. A product used for triglyceride lowering without a cardiovascular-risk-reduction indication would not automatically practice claim 1.

The phrase “about 4 g” creates a numerical claim-construction issue. A court would ordinarily assess the term in the context of the specification, prosecution history, clinical evidence, and ordinary pharmaceutical dosing practice. A four-gram daily regimen is the commercial dosing pattern associated with Vascepa, generally administered as two 1-gram capsules twice daily with food.

The phrase “period effective to reduce risk” is functional. It links the treatment period to the claimed clinical result but does not require that a physician prove, for each individual patient, that revascularization risk actually declined. The claim is directed to a treatment method supported by the clinical evidence and intended to produce the stated outcome.

What do claims 2 through 9 add?

The dependent claims create narrower fallback positions. They do not expand claim 1.

Claim	Added limitation	Practical significance
2	Fasting baseline triglycerides of about 135 to about 500 mg/dL and LDL-C of about 40 to about 100 mg/dL	Narrows the population by baseline lipid values
3	Ethyl icosapentate is at least about 96 wt.% of all omega-3 fatty acids in the composition	Distinguishes highly purified icosapent ethyl from mixed omega-3 products
4	Approximately 1 gram of composition is present in each of four capsules	Aligns the method with a four-capsule, 4-gram daily regimen
5	Treatment period ends at least two years after initial administration	Adds a minimum treatment duration
6	Subject is on statin therapy	Ties treatment to background statin use
7	Triglycerides are at least 135 mg/dL and subject is on statin therapy	Combines lipid and statin limitations
8	Triglycerides are at least 135 mg/dL	Narrows the population by triglyceride level
9	Claim 8 population is also on statin therapy	Creates another statin-plus-triglyceride fallback

Claims 7 and 9 are similar in commercial effect, but they depend from different claims. Claim 7 depends directly from claim 1. Claim 9 depends from claim 8. The dependency structure can matter if a court finds one parent claim invalid or interprets different limitations differently.

What formulations are protected by the '270 patent?

The formulation limitation appears principally in claims 3 and 4.

Claim 3 requires that ethyl icosapentate account for at least approximately 96% by weight of all omega-3 fatty acids in the pharmaceutical composition. This limitation is directed to purity within the omega-3 fraction. It is not necessarily a requirement that 96% of the entire capsule mass consist of ethyl icosapentate.

Claim 4 reflects a dosage form containing approximately 1 gram of the pharmaceutical composition in each of four capsules. The claim therefore targets a product configuration consistent with four 1-gram capsules per day.

The claims do not appear, based on the supplied claim set, to require a particular capsule shell, excipient, coating, manufacturing process, particle size, storage condition, or release profile. Those matters may be protected by separate formulation or composition patents in the wider Vascepa portfolio.

A generic icosapent ethyl capsule could therefore face two distinct questions:

• Whether its formulation satisfies the purity and capsule limitations in claims 3 and 4.
• Whether its labeling and intended use satisfy the cardiovascular-risk-reduction limitations in claims 1, 6, 7, 8, or 9.

When does U.S. Patent 10,792,270 lose exclusivity?

The Orange Book-listed patent expiration date is generally reported as December 1, 2033. The date should be distinguished from FDA regulatory exclusivity.

Exclusivity right	Status
Patent protection under the '270 patent	Reported through December 1, 2033
New chemical entity exclusivity	Expired before the cardiovascular indication approval
Cardiovascular indication exclusivity	Separate FDA regulatory exclusivity period, not a substitute for the patent
Pediatric exclusivity	Must be assessed from the applicable FDA records and may extend listed patent or exclusivity dates when granted
Generic approval timing	Controlled by ANDA certifications, litigation outcomes, settlements, and any applicable exclusivity

The '270 patent does not create a new chemical entity exclusivity period. Ethyl icosapentate had been approved for triglyceride lowering before FDA approved Vascepa for cardiovascular-risk reduction in December 2019.

The practical patent expiry question is not simply whether the patent remains unexpired. A generic company may seek approval before expiry by filing a Paragraph IV certification and challenging validity, enforceability, or infringement.

What is the Orange Book status of the '270 patent?

The patent has been associated with the Vascepa regulatory patent estate and is relevant to the FDA Orange Book framework for approved drug products. Orange Book listing gives the patent holder an opportunity to receive notice of a Paragraph IV certification and to bring patent litigation within the statutory period.

An Orange Book listing does not establish that the patent is valid or infringed. It identifies a patent that the NDA holder or patent owner represents as covering the approved drug or an approved method of using the drug.

For Vascepa, the relevant Orange Book landscape has included multiple patents directed to:

• Cardiovascular-risk-reduction methods
• High-purity icosapent ethyl compositions
• Dosage regimens
• Patient populations
• Manufacturing or product characteristics

The '270 patent should therefore be analyzed as one layer of a portfolio rather than as the sole barrier to generic entry.

Which companies have challenged Vascepa patents?

The principal U.S. generic challengers have included Hikma Pharmaceuticals and Dr. Reddy's Laboratories. Both companies pursued abbreviated new drug application pathways for generic icosapent ethyl.

Company	Product	Regulatory pathway	Commercial relevance
Hikma Pharmaceuticals	Generic icosapent ethyl capsules	ANDA	Entered the U.S. generic market after patent disputes and related arrangements
Dr. Reddy's Laboratories	Generic icosapent ethyl capsules	ANDA	Challenged Vascepa-related patent protection and commercialized a generic product
Other ANDA applicants	Generic icosapent ethyl	ANDA	Potentially subject to individual certifications, settlements, and launch restrictions

The major litigation involving Vascepa did not turn solely on the '270 patent. Amarin asserted multiple patents against generic applicants. The disputes included patents covering cardiovascular-risk-reduction methods and product characteristics.

In Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., the Federal Circuit affirmed a district court judgment that asserted Vascepa patents were invalid for obviousness. The case materially weakened Amarin's ability to block generic icosapent ethyl based on the asserted patent group.[1]

That decision did not mean every Vascepa patent was automatically invalid. Patent validity is claim-specific and patent-specific. The commercial result was that generic companies obtained a substantially clearer path to market than Amarin's pre-litigation patent strategy contemplated.

What Paragraph IV risks exist for generic icosapent ethyl?

A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

For the '270 patent, a generic applicant could develop several principal theories:

Noninfringement

A generic applicant could argue that its labeling omits the claimed cardiovascular-risk-reduction method or that it does not encourage administration in the claimed patient population.

The risk increases if the generic label includes:

• Established cardiovascular disease
• Reduction of cardiovascular events or coronary revascularization
• Four-gram daily dosing
• Use with statins
• Triglyceride thresholds overlapping the claims

A label carve-out could reduce method-of-use exposure if FDA permits removal of the patented indication and the remaining label does not actively encourage the claimed use. The commercial value of a carve-out depends on whether physicians, payors, treatment guidelines, and the reference label still make the patented use foreseeable.

Invalidity

The core invalidity theories would likely involve obviousness, anticipation, written description, enablement, and indefiniteness.

The most substantial obviousness issue is whether the claimed patient population, four-gram dose, statin background therapy, triglyceride range, and cardiovascular outcome were predictable from prior omega-3 literature and clinical trials. The REDUCE-IT results provided important evidence for the cardiovascular indication, but patent validity is assessed under the statutory obviousness framework rather than solely by the existence of positive clinical results.

Indefiniteness

Terms such as “about 4 g,” “about 135 mg/dL,” “about 500 mg/dL,” and “period effective to reduce risk” could generate claim-construction disputes. These terms are common in pharmaceutical patents, but their legal sufficiency depends on the specification and prosecution record.

Written description and enablement

A challenger could argue that the patent does not adequately support every combination of patient characteristics, dosing conditions, treatment durations, and clinical outcomes covered by the claims. The narrower dependent claims may be more defensible if the patent specification contains detailed clinical and formulation support.

How strong is the patent estate for Vascepa?

The Vascepa estate has meaningful historical value but a weaker blocking position after generic litigation losses and commercial generic entry.

Strength factor	Assessment
Clinical differentiation	Strong; REDUCE-IT supplied cardiovascular-outcome data not shared by all omega-3 products
Composition differentiation	Stronger for high-purity icosapent ethyl than for broad omega-3 formulations
Method-of-use breadth	Moderate; the claims require a defined disease state and approximately 4-gram dosing
Litigation resilience	Reduced after adverse obviousness rulings against asserted patents
Manufacturing barrier	Limited for capable generic manufacturers; the active ingredient is a defined small-molecule ester
Formulation barrier	Moderate where high purity, capsule loading, and product specifications are required
Commercial blocking power	Reduced by approved generic products and insurer substitution
Biosimilar protection	Not applicable; icosapent ethyl is a small molecule, not a biologic

The strongest commercial distinction is the clinical use of purified icosapent ethyl in statin-treated patients with cardiovascular risk. The weakest point is that the product is a small molecule administered in conventional oral capsules, with no biologic manufacturing barrier.

What patent litigation affects Vascepa?

The central litigation risk arose from Amarin's efforts to enforce patents against generic icosapent ethyl applicants. The litigation included claims directed to the REDUCE-IT cardiovascular-risk-reduction population and related product characteristics.

The Federal Circuit's decision in the Hikma dispute affirmed invalidity findings concerning asserted patents and allowed generic competition to proceed.[1] That outcome changed the value of later-expiring method patents, including patents in the same broader cardiovascular-risk-reduction portfolio.

The '270 patent's expiration date alone does not establish effective exclusivity through 2033. The relevant assessment must include:

• Whether the patent remains enforceable
• Whether it has been invalidated or disclaimed
• Whether a generic applicant has made a Paragraph IV certification
• Whether the generic label includes the claimed use
• Whether a settlement restricts launch
• Whether later-issued continuation patents remain enforceable
• Whether the FDA-approved label supports a skinny-label strategy

How does the '270 patent compare with composition and formulation patents?

Patent category	What it protects	Generic risk
Method-of-use patent	Treating a defined patient population for cardiovascular-risk reduction	Label and inducement risk
Composition patent	High-purity ethyl icosapentate or defined omega-3 composition	Product infringement risk
Formulation patent	Capsule structure, excipients, concentration, or stability	Product-development and ANDA risk
Manufacturing patent	Processes for producing or purifying icosapent ethyl	Process-use risk, often harder to detect
Regulatory exclusivity	FDA approval rights for a defined indication or product	Approval-timing barrier rather than ordinary patent protection

The '270 patent is more vulnerable to a label-based noninfringement strategy than a composition patent. A generic company can potentially manufacture the same active ingredient while contesting whether its approved label practices the patented cardiovascular use.

A composition or manufacturing patent can create stronger protection if infringement can be shown from the generic product itself. Those patents may also be more difficult to avoid through a skinny-label approach.

What generic launch scenarios exist?

Three launch scenarios are most relevant.

At-risk launch before patent expiry

A generic applicant may launch after receiving FDA approval but before final resolution of all patent disputes. This creates potential damages exposure if the patent is later upheld and found infringed.

Launch with a carved-out label

The generic may omit the patented cardiovascular-risk-reduction indication while retaining an unpatented triglyceride-lowering indication. This approach reduces direct method-of-use exposure but can generate inducement disputes if the remaining label, marketing, or clinical environment encourages the patented use.

Delayed or settlement-based launch

A settlement may specify a launch date before patent expiration, subject to business terms, authorized generic arrangements, or other restrictions. Settlement dates can materially change the commercial value of the nominal 2033 patent expiration.

What is the revenue exposure from generic competition?

Vascepa revenue declined after generic icosapent ethyl entered the U.S. market. Amarin reported U.S. Vascepa product revenue of approximately $614 million in 2020 and approximately $582 million in 2021, before generic erosion became more pronounced.[2,3]

Generic entry affects revenue through:

• Lower net pricing
• Pharmacy substitution
• Formulary exclusion or preferred generic placement
• Reduced prescriber loyalty
• Greater payer pressure
• Declining value of long-dated method patents

The commercial value of the '270 patent is therefore better measured by incremental protection against a cardiovascular-indication generic than by the remaining nominal patent term.

Is there biosimilar risk for icosapent ethyl?

No biosimilar pathway applies. Icosapent ethyl is a small-molecule active pharmaceutical ingredient, so competing products use the ANDA generic-drug pathway rather than the Public Health Service Act biosimilar pathway.

The principal risks are ordinary generic substitution, Paragraph IV litigation, label carve-outs, formulation design-arounds, and potential authorized-generic competition.

Key Takeaways

• U.S. Patent 10,792,270 claims approximately 4 grams per day of ethyl icosapentate to reduce coronary revascularization risk in subjects with established cardiovascular disease.
• Dependent claims narrow the population by triglyceride level, LDL-C level, statin use, treatment duration, omega-3 purity, and four-capsule dosing.
• The patent is a method-of-use patent, not a broad composition or manufacturing patent.
• Its reported Orange Book expiration is December 1, 2033.
• The patent’s practical strength is limited by the ability of generic applicants to pursue Paragraph IV challenges and label-based noninfringement positions.
• Hikma and Dr. Reddy's were major generic challengers in the Vascepa patent landscape.
• Federal Circuit litigation materially weakened Amarin's ability to use the broader Vascepa patent estate as a barrier to generic entry.
• Icosapent ethyl has generic, not biosimilar, competition risk.
• The patent’s commercial value depends more on enforceability, label scope, and settlement terms than on its nominal 2033 expiration date.

FAQs About U.S. Patent 10,792,270

Does the '270 patent cover all uses of Vascepa?

No. It covers a defined cardiovascular-risk-reduction method involving approximately 4 grams per day and a subject with established cardiovascular disease. It does not claim every triglyceride-lowering use.

Does taking four 1-gram capsules necessarily infringe the patent?

No. Capsule count alone is insufficient. Infringement would require the claimed patient population, therapeutic purpose, dose, and other applicable limitations.

Can a generic sell icosapent ethyl for triglyceride lowering?

Potentially. A generic may seek approval with a label that excludes a patented cardiovascular indication, subject to FDA approval and inducement risks.

Does the 2033 expiration date guarantee Vascepa market exclusivity until 2033?

No. Generic entry can occur through invalidity findings, noninfringement, settlements, authorized-generic arrangements, or other regulatory and litigation outcomes.

Is the 96% omega-3 purity requirement present in every claim?

No. The 96 wt.% limitation appears in claim 3. It is not a limitation of independent claim 1 unless claim 3 is the asserted claim.

References

1. United States Court of Appeals for the Federal Circuit. (2023). Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 64 F.4th 1372. https://www.cafc.uscourts.gov/

2. Amarin Corporation plc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020. https://ir.amarin.com/

3. Amarin Corporation plc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021. https://ir.amarin.com/

4. U.S. Food and Drug Administration. (2019). FDA approves use of Vascepa to reduce risk of cardiovascular events in certain patients. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. United States Patent and Trademark Office. (2020). U.S. Patent No. 10,792,270. https://patents.google.com/patent/US10792270B2/en

Drugs Protected by US Patent 10,792,270

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes	10,792,270					USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No	10,792,270					USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE

International Family Members for US Patent 10,792,270

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013282394
Australia	2018204499
Australia	2020294210
Brazil	112014032905
Canada	2877514
Canada	3067008
Canada	3067012